+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chlamydia Infections - Pipeline Review, H2 2019

  • ID: 4866509
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 68 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Abera Bioscience AB
  • BlueWillow Biologics Inc
  • Genetic Immunity Inc
  • Microbiotix Inc
  • QureTech Bio AB
  • Vault Pharma Inc
  • MORE
Chlamydia Infections - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections - Pipeline Review, H2 2019, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.

Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 11 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abera Bioscience AB
  • BlueWillow Biologics Inc
  • Genetic Immunity Inc
  • Microbiotix Inc
  • QureTech Bio AB
  • Vault Pharma Inc
  • MORE
Introduction
Report Coverage
Chlamydia Infections - Overview
Chlamydia Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chlamydia Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chlamydia Infections - Companies Involved in Therapeutics Development
Abera Bioscience AB
Abivax SA
BlueWillow Biologics Inc
Evofem Biosciences Inc
Genetic Immunity Inc
Lawrence Livermore National Laboratory
Lead Discovery Center GmbH
Merck & Co Inc
Microbiotix Inc
Prokarium Ltd
QureTech Bio AB
SATT IDF Innov SAS
Vault Pharma Inc
Vaxine Pty Ltd
Yaso Therapeutics Inc
Chlamydia Infections - Drug Profiles
Ab-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABX-196 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Amphora - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ChlamyDerm - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia trachomatis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEG-2S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit CPAF for Chlamydia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPCM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Chlamydia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 16S rRNA for Gonorrhea and Chlamydia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPI-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia Infections - Dormant Projects
Chlamydia Infections - Product Development Milestones
Featured News & Press Releases
Aug 13, 2019: Progress made in developing first Chlamydia vaccine
Apr 20, 2017: New weapon in fight against antibiotic resistance discovered
Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice
Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology
Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia
Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection
Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Chlamydia Infections, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
Table 8: Number of Products by Stage and Route of Administration, H2 2019
Table 9: Number of Products by Stage and Molecule Type, H2 2019
Table 10: Chlamydia Infections - Pipeline by Abera Bioscience AB, H2 2019
Table 11: Chlamydia Infections - Pipeline by Abivax SA, H2 2019
Table 12: Chlamydia Infections - Pipeline by BlueWillow Biologics Inc, H2 2019
Table 13: Chlamydia Infections - Pipeline by Evofem Biosciences Inc, H2 2019
Table 14: Chlamydia Infections - Pipeline by Genetic Immunity Inc, H2 2019
Table 15: Chlamydia Infections - Pipeline by Lawrence Livermore National Laboratory, H2 2019
Table 16: Chlamydia Infections - Pipeline by Lead Discovery Center GmbH, H2 2019
Table 17: Chlamydia Infections - Pipeline by Merck & Co Inc, H2 2019
Table 18: Chlamydia Infections - Pipeline by Microbiotix Inc, H2 2019
Table 19: Chlamydia Infections - Pipeline by Prokarium Ltd, H2 2019
Table 20: Chlamydia Infections - Pipeline by QureTech Bio AB, H2 2019
Table 21: Chlamydia Infections - Pipeline by SATT IDF Innov SAS, H2 2019
Table 22: Chlamydia Infections - Pipeline by Vault Pharma Inc, H2 2019
Table 23: Chlamydia Infections - Pipeline by Vaxine Pty Ltd, H2 2019
Table 24: Chlamydia Infections - Pipeline by Yaso Therapeutics Inc, H2 2019
Table 25: Chlamydia Infections - Dormant Projects, H2 2019

List of Figures
Figure 1: Number of Products under Development for Chlamydia Infections, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Targets, H2 2019
Figure 5: Number of Products by Stage and Targets, H2 2019
Figure 6: Number of Products by Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abera Bioscience AB
  • Abivax SA
  • BlueWillow Biologics Inc
  • Evofem Biosciences Inc
  • Genetic Immunity Inc
  • Lawrence Livermore National Laboratory
  • Lead Discovery Center GmbH
  • Merck & Co Inc
  • Microbiotix Inc
  • Prokarium Ltd
  • QureTech Bio AB
  • SATT IDF Innov SAS
  • Vault Pharma Inc
  • Vaxine Pty Ltd
  • Yaso Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll